- ¹ Chlorosphaerolactylates A-D: the natural
- ² chlorinated lactylates isolated from the Portuguese
- 3 cyanobacteria Sphaerospermopsis sp. LEGE
- 4 00249

5 AUTHOR NAMES

6 Ignacio Gutiérrez del Río^{‡,0}, Nelly Brugerolle de Fraissinette^{†,0}, Raquel Castelo Branco^{†,0},

7 Flavio Oliveira[†], João Morais[†], Saúl Redondo Blanco[‡], Claudio J. Villar[‡], María José

8 Iglesias[§], Raquel Soengas[§], Virginio Cepas¹, Yuly López Cubillos¹, Giacomo Sampietro^{||},

9 Liliana Rodolfi^{||}, Felipe Lombó[‡], Sara M. Soto González[⊥], Fernando López Ortiz^{§,*}, Vitor

10 Vasconcelos^{\dagger, ∇}, Mariana A. Reis^{$\dagger, *$}

11

12 AUTHOR ADDRESS

13 † Interdisciplinary Centre of Marine and Environmental Research (CIIMAR/CIMAR),
14 Terminal de Cruzeiros do Porto de Leixões, University of Porto, 4450-208 Matosinhos,
15 Portugal

- 16 ∇ Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre, Edifício FC4, 416917 007 Porto, Portugal
- 18 ‡ Universidad de Oviedo (Área de Microbiología, Departamento de Biología Funcional),
- 19 IUOPA (Instituto Universitario de Oncología del Principado de Asturias), IISPA (Instituto de

- 20 Investigación Sanitaria del Principado de Asturias), Research Unit "Biotechnology in
- 21 Nutraceuticals and Bioactive Compounds-BIONUC". Oviedo, Spain
- 22 § Área de Química Orgánica, Research Centre CIAIMBITAL, Universidad de Almería, Ctra.
- 23 Sacramento s/n, 04120, Almería, Spain.
- 24 LISGlobal, Hospital Clínic—Universitat de Barcelona, 08036 Barcelona, Spain
- 25 || Fotosintetica & Microbiologica S.r.l., Via dei Della Robbia 54, 50132 Firenze, Italy

27 ABSTRACT

28 The unprecedented natural chlorinated lactylates, chlorosphaerolactylates A-D (1-4), were 29 isolated from the methanolic extract of the cyanobacteria Sphaerospermopsis sp. LEGE 00249 through a combination of bioassay-guided and MS-guided approaches. Compounds 1-4 are 30 esters of (mono-, di- or tri-)chlorinated lauric acid and lactic acid, whose structures were 31 32 assigned on the basis of spectrometric and spectroscopic methods inclusive of 1D and 2D NMR experiments. High-resolution mass-spectrometry datasets also demonstrated the existence of 33 34 other minor components that were identified as chlorosphaero(bis)lactylates analogues. The chlorosphaerolactylates were tested for potential antibacterial, antifungal and antibiofilm 35 36 properties using bacterial and fungal clinical isolates. Compounds 1-4 inhibited the growth of Staphylococcus aureus S54F9 and Candida parapsilosis SMI416, as well as, affected the 37 biofilm formation of coagulase-negative Staphylococcus FI31. 38

39 Introduction

In the past few decades, cvanobacteria have been considered as one of the most promising 40 groups of bacteria for natural products discovery.^{1,2} Owing to the distinct ecological niches that 41 these organisms occupy and their particular ecophysiology, the natural products synthesized 42 by cyanobacteria are diverse and structurally unique.³ These metabolites could be peptides, 43 polyketides, derivatives of fatty acids and hybrids thereof, many featuring unusual 44 modifications such as halogenation.⁴ More than 4000 halogenated compounds have been 45 isolated from natural sources including bacteria, fungi, algae, higher plants, invertebrates and 46 vertebrates from distinct environments^{5,6} Furthermore, the presence of halogen substituents 47 48 (such as chlorine, bromine and more rarely iodine and fluorine) in natural products influences their biological activity⁷, representing a valuable and expanding class of natural products. In 49 50 the last decades, several halogenated fatty acids amide derivatives were isolated from marine 51 cyanobacteria including the malyngamides⁸, the jamaicamides⁹, the grenadamides¹⁰, and the columbamides¹¹. These compounds have been associated with biological activities such as 52 cytotoxicity, calcium and sodium channel modulation and cannabinoid receptor binding. 53 54 Additional examples of halogenated fatty acids incorporated in natural peptides can be found in the literature, such as the puwainaphycins originating from a terrestrial cyanobacterium¹² or 55 lyngbyabellin extracted from the marine cyanobacteria Lyngbya majuscula¹³. Moreover, the 56 unusual and fascinating class of chlorosulfolipids was reported in a *Nostoc* sp. strain¹⁴ and 57 more recently aranazoles, extensively polychlorinated compounds were described in a 58 Fischerella sp. strain¹⁵, proving once again the wide structural diversity of halogenated 59 60 metabolites that cyanobacteria are capable to produce.


61 Our current interest in identifying novel cyanobacterial metabolites with antibiotic and 62 antibiofilm activity in the framework of the NoMorFilm project¹⁶ led us to investigate the 63 chemical diversity of strains from our in-house cyanobacteria Culture Collection (Blue 64 Biotechnology and Ecotoxicology Culture Collection – LEGE CC). Through a bioassay-guided 65 approach, Sphaerospermopsis sp. LEGE 00249 was pinpointed as a promising producer of antibiofilm and antibacterial metabolites. This cyanobacterial strain was isolated from a 66 67 Portuguese freshwater reservoir and was previously reported as producer of a prenylated cyanobactin, a cyclic peptide produced by ribosomal synthesis.¹⁷ Herein, we describe the 68 69 detection, isolation, structural elucidation and bioactivity of four novel chlorinated fatty acid 70 lactylates of cyanobacterial origin, the chlorosphaerolactylates $\mathbf{A} - \mathbf{D}$ (1-4). Morever, detection 71 correspondent to compounds of the chlorosphaerolactylate type of masses or 72 chlorosphaerobislactylate type are also reported.

73

74 **Results and discussion**

75 We have recently reported a preliminary screening concerning inhibition of microbial biofilm formation by cyanobacterial organic extracts.¹⁶ As a result, the methanolic extract of the strain 76 77 Sphaerospermopsis sp. LEGE 00249 was selected as promising for isolation of active 78 compounds. In this way, this cyanobacterial strain was regrown (50 L laboratory scale) and its 79 biomass was sequentially extracted with hexane, ethyl acetate and methanol, and the later was 80 submitted to bioassay-guided fractionation, assisted by HPLC, on the basis of the growth inhibition of the clinical isolate *Staphylococcus aureus* S54F9¹⁸ (Supporting Information (SI), 81 82 Figure S18). Analysis of the active fractions by HRESIMS yielded six groups (G1-G6; Figure 83 1) that were defined according to their chemical composition. The presence of differential mass 84 peaks showing typical chlorine isotope patterns, indicated the fractions to contain compounds 85 bearing one, two or three chlorine atoms (SI; Figure S19). More specifically, group G2 86 presented the isotope pattern at m/z 339/341/343 (100:69.9:11 ratio) consistent with the 87 presence of two chlorine atoms in the molecule $(m/z 339.1117 [M-H]^-; C_{15}H_{26}Cl_2O_4)$ and group 88 G3 showed the isotope cluster at m/z 373/375/377/379 (100:92.8:30.9:3.5 ratio) indicating the 89 molecule to bear three chlorine substituents (m/z 373.0707 [M-H]⁻; C₁₅H₂₅Cl₃O₄). Furthermore, 90 groups G4 and G5 showed the isotope pattern at m/z 305/307 (100:32.7 ratio) consistent with the presence of only one chlorine atom $(m/z, 305.1504 \text{ [M-H]}^- \text{ and } m/z, 305.1509 \text{ [M-H]}^-$, 91 92 respectively; C₁₅H₂₇ClO₄). Although G4 and G5 showed to have peaks with the same mass, 93 these presented different retention times (SI; Figure S19), suggesting these molecules to be 94 structural isomers. Finally, the chlorine isotopic patterns in groups G1 and G6 presented low 95 intensity (close to the baseline) and were not suitable for NMR experiments.

96




98 Figure 1. Bioassay-guided discovery of antibacterial compounds. Schematic representation of 99 the 96-well plate showing the active fractions (F31-F48) that inhibited the growth of 100 *Staphylococcus aureus* S54F9 (clinical isolate). The groups G1-G6 were defined according to 101 their chemical composition.

102

103 The structure of compounds **1-4** (Figure 2) was elucidated through the combination of 104 spectroscopic and spectrometric methods. They were identified as esters of chlorinated lauric 105 acid and lactic acid. Nevertheless, the amounts isolated from the 50 L culture were not enough 106 to establish an unambiguous structural elucidation of compound **4** neither for the evaluation of 107 the antibiofilm activity, and thus, the cyanobacterial strain was regrown using Green Wall 108 Panel (GWP®-III) outdoor photobioreactors. The compounds **1-4** were then isolated from this


- 109 biomass guided by mass spectrometry, though compounds **2** and **3** were not possible to purify
- 110 and were always isolated as a mixture.



112 **Figure 2**. Planar structures of chlorosphaerolactylates A – D (1-4).

113

Compound 1, named as chlorosphaerolactylate A was obtained as a light-green oil $([\alpha]^{24}_D)$ 114 115 +34.1). The molecular formula $C_{15}H_{26}Cl_2O_4$, consistent with two degrees of unsaturation, was 116 deduced from the HRESIMS spectrum showing the deprotonated molecule mass peak at m/z339.1117 [M - H]⁻ (calcd for C₁₅H₂₅Cl₂O₄, 339.1135). The IR spectra showed a broad 117 absorption band in the range 3019-2797 cm⁻¹ (v-shaped) along with absorptions at 1736 and 118 1725 cm⁻¹ suggesting the presence of two O=C-OR moieties, one of them being a carboxyl 119 functional group (R = H). These findings were corroborated by the ¹³C NMR signals at δ 175.1 120 (broad) and 174.7 ppm and account for the two degrees of unsaturation. The 2D HSQC-edited 121 122 spectrum showed that the remaining thirteen carbon atoms consisted of one CH₃, ten CH₂ and 123 two CH (Table 1). The structural assignment was based on the analysis of the correlations observed in the 2D HMBC, HSQC-edited and COSY NMR spectra. The methine C2, C6' and 124 methylene carbons C2', C12' were easily identified on chemical shift grounds. Key 125 126 connections deduced from the HMBC and COSY spectra used to establish the connectivity along the carbon skeleton are shown in Figure 3. Starting with the HMBC spectrum, the doublet 127 128 at δ 1.46 (J = 7.2 Hz) ppm of the methyl group H3 showed three correlations with the methine 129 carbon C2 at δ 70.3 ppm and with the two carbonyl carbons C1/C1' at δ 175.1/174.7 ppm. The 130 correlation of the methylene protons H2' (multiplet, δ 2.4 ppm) with the most shielded signal indicated that it belongs to C1' (δ 174.7 ppm). H2' also correlated with C3' (δ 25.4 ppm) and 131 132 C4' (δ 27.0 ppm). The distinction between the two carbons was achieved through the 133 identification of H3' (m, δ 1.65 ppm) via its COSY correlation with H2' and the subsequent 134 HSQC correlation of H3' with the carbon atom to which it is directly bonded. The same strategy 135 was applied to assign the three methylene groups at the other end of the molecule. The triplet 136 at δ 3.56 (J = 6.7 Hz) ppm resulting from the protons H12' correlated with C10' (δ 27.8 ppm) 137 and C11' (δ 33.7 ppm) in the HMBC spectrum. The latter was assigned based on the H12', 138 H11' (m, δ 1.77 ppm) and H11', C11' correlations observed in the COSY and HSQC spectra, 139 respectively. The carbons at position C10' and C11' also showed correlation with the 140 diastereotopic protons H9a'/H9b' (m, δ 1.35 and 1.37 ppm) which in turn correlated with two 141 additional carbon atoms at δ 27.4 and 39.5 ppm. They must correspond to C8' and C7', respectively. This assignment was supported by the COSY correlations of H6' (m, δ 3.93 ppm) 142 143 with H5a'/H7a' and H5b'/H7b' (m, δ 1.77 and 1.69 ppm). Once the carbon skeleton was 144 assigned, the correlations observed in the HSQC spectrum provided the identification of the 145 protons attached to each carbon atom (Table 1).



147 Figure 3. Key COSY and HMBC correlations of chlorosphaerolactylate A (1)

Table 1. ¹H NMR (600.13 MHz) and ¹³C NMR (150.9 MHz) spectroscopic data for compounds

1-4.

	chlorosphaerolactylate		chlorosphaerolactylate		chlorosphaerolactylate		chlorosphaerolactylate	
	A (1)		B (2)		C (3)		D (4)	
position	$\delta_H (J ext{ in }$	δ_{C}	$\delta_H (J \text{ in }$	δ_C	$\delta_{H} \left(J ext{ in } ight)$	δ_{C}	$\delta_H(J ext{ in }$	δ_{C}
	Hz)		Hz)		Hz)		Hz)	
1		175.1 (b) ^a		176.5 (b) ^a		175.6		178.7 (b) ^a
						(b) ^a		
2	4.99, q	70.3	4.99, q	71.2	4.99, q	70.6	4.91, q	72.7
	(7.2)		(7.1)		(7.1)		(7.1)	
3	1.46, d	17.4	1.44, d	17.7	1.45, d	17.6	1.42, d	18.2
	(7.2)		(7.1)		(7.1)		(7.1)	
1'		174.7		175.1		174.7		175.1
2'	2.40, m	34.6	2.37, m	34.9	2.41, m	34.7	2.4, m	34.9
3'	1.65, m	25.4	1.62, m	25.9	1.64, m	25.4	1.64, m	25.4
					1.67, m			
4'	1.48, m	27.0	1.35, m	30.2	1.49, m	27.0	1.47, m	27.1
	1.59, m				1.59, m		1.57, m	
5' b	1.69, m	39.3	1.33, m	30.4	1.68, m	39.3	1.69, m	39.3
а	1.77, m				1.78, m		1.78, m	
6'	3.93, m	64.8	1.32, m		3.92, m	64.9	3.94, m	64.8
7' b	1.69, m	39.5	1.32, m	-	1.66, m	39.7	1.69, m	39.4
а	1.77, m			30.5 (1C) ^b	1.76, m		1.78, m	
8' b	1.48, m	27.4	1.32, m	30.6 (2C) ^b	1.32, m	30.0	1.45, m	27.3
a	1.56, m						1.56, m	
9' b	1.35, m	29.5	1.34, m	30.0	1.42, m	27.54	1.38, m	29.1
a	1.37, m				1.53, m			
10'	1.46, m	27.8	1.44, m	27.9	1.30, m	32.9	1.57, m	26.9
11'	1.77, m	33.7	1.75, m	33.8	1.33, m	23.6	2.19, m	44.7

12'	3.56, t	45.7	3.55, t	45.7	0.91, t	14.4	5.99, t	75.0
	(6.7)		(6.6)		(7.0)		(6.1)	

151

^a Broad signal. ^b Could not be assigned unambiguously. All spectra recorded in CD₃OD. 152

153 An analogous assignment strategy was applied to the elucidation of the structures of 154 compounds 2, 3 and 4 (Table 1). They showed the same molecular skeleton than compound 1 155 only differing in the number and/or position of the chlorine atoms bound to the lauryl moiety. 156 Chlorosphaerolactylate B (2) and chlorosphaerolactylate C (3) were isolated as light-yellow 157 oils. They are positional isomers of molecular formula $C_{15}H_{27}ClO_4$ with a HRESIMS peak at 158 m/z 305.1504/305.1509 [M-H]⁻ for 2/3 (calculated m/z = 305.1525). The position of the 159 chlorine atom in each compound was easily determined through the analysis of the 1D and 2D 160 NMR spectroscopic data. For compound 2, six methylene protons appeared overlapped in the 161 chemical shift range of $\delta 1.30 - 1.37$ ppm. The correlations originating from the well-resolved 162 signals of the methylene groups at positions 2' (H2', δ 2.37 ppm, m; C2' δ 34.9 ppm) and 12' (H12', δ 3.55 ppm, t, J 6.6 Hz; C12' δ 45.7 ppm) provided the connectivity along the fragments 163 164 C2'-C5' and C12'-C9', respectively. However, the overlap of signals in the ¹H and ¹³C NMR spectra of the methylene groups 6' to 8' prevented their unequivocal assignment. As in 165 166 compound 1, the distinguishing feature of the chlorine substituent at C6' (H6', δ 3.92 ppm, m; C6' δ 64.9 ppm) of compound **3** allowed for the proper assignment of the neighboring 167 168 methylene groups (H5', δ 1.68 ppm, m; C5' δ 39.3 ppm; H7' δ 1.66 ppm, m; C7' δ 39.7 ppm). 169 Compound 4 (chlorosphaerolactylate D) consisted of a light-green oil. The HRESIMS 170 spectrum showed a peak at $m/z = 373.0707 \text{ [M-H]}^{-1}$ consistent with a molecular formula of $C_{15}H_{25}Cl_{3}O_{4}$ (calculated m/z = 373.0740 for [M-H]⁻). Two of the three chlorine atoms are 171 172 bound to the terminal carbon of the lauric acid chain as evidenced by the ¹H (H12', δ 5.99 ppm, t, J 6.1 Hz) and ¹³C (C12' δ 75.0 ppm) chemical shifts of the methine group C12'. The location 173 174 of the third chlorine atom at C6' (H6', δ 3.94 ppm, m; C6' δ 64.8 ppm) was achieved through the observation in the HMBC and COSY NMR spectra of the same set of correlations withneighboring protons as those described above for compound 1 (Figure 3).

177 The stereocenters at C2 for compounds 1-4 and at C6' for compounds 1 and 3 remain with its 178 configuration unknown at present. Further biosynthetic investigations or synthetic studies will 179 be key to ascertain this point.

180 Besides the particularity of halogenation found in these novel metabolites, they relate closely 181 to lactylates, which are widely used as emulsifying agents in food and cosmetic industries. In 182 general, lactylates are considered to have non-toxic effects to humans, as well as, biodegradable properties, making them very interesting for industrial applications.¹⁹⁻²² Given the 183 184 biotechnological potential of our findings, attention was directed to the minor components of 185 fractions F31-F48 (Figure 1). Thus, further HRESIMS analysis pinpointed for the putative 186 existence of other novel mono-, di-, and tri-chlorinated fatty acid lactylate-like compounds 187 (Table 2). The presence of other novel positional isomers of compounds 1-4 was suggested 188 through the detection of the same m/z but at different retention times (SI; Figure S23-S26). 189 Moreover, detailed analysis of the ions generated by the in-source fragmentation pointed to 190 compounds bearing one more unit of lactic acid, the mono-, di-, and tri-chlorinated bislactylates 191 (Figure 4; Table 2). To confirm these observations, in-source fragmentation of a commercial 192 standard of sodium lauroyl lactylate containing a mixture of 23:9:1.33 2-(dodecanoyloxy) 193 propanoic acid (C₁₅H₂₈O₄), 2-((2-(dodecanoyloxy)propanoyl)oxy)propanoic acid (C₁₈H₃₂O₆) 194 and 2-((2-((2-((2-((dodecanoyloxy))propanoyl)))) propanoic acid (C₂₁H₃₆O₈) acid 195 was also investigated. The in-source-formed species evidenced the expected loss of $C_3H_4O_2$ 196 corroborating the same fragmentation pattern as observed for the chlorosphaerobislactylates 197 (SI, Figures S20-S22).

Table 2. HRESIMS-based detection of putative chlorinated fatty acid lactylates in fractions

200 F31-F49.

	Analytical Error (mmu)	Proposed Molecular Formula	<i>m/z</i> [M-H] ⁻
Difference to compounds 2 and 3	nds	Mono- chlorinated compou	
Putative positional isomer	0.0020	$C_{15}H_{27}ClO_4$	305.1504
CUO (mutations his la stalata)	0.0029	$C_{18}H_{31}ClO_6$	377.1707
+ C ₃ H ₄ O ₂ (putative bis-lactylate);	0.0039	$C_{18}H_{31}ClO_6$	377.1697
positional isomers	0.0034	$C_{18}H_{31}ClO_6$	377.1702
Difference to compound 1	ls	Di- chlorinated compound	
	0.0030	$C_{15}H_{26}Cl_2O_4$	339.1105
Dutative positional isomer	0.0028	$C_{15}H_{26}Cl_2O_4$	339.1107
Putative positional isomer	0.0030	$C_{15}H_{26}Cl_2O_4$	339.1105
	0.0032	$C_{15}H_{26}Cl_2O_4$	339.1103
+ C ₃ H ₄ O ₂ (putative bis-lactylate)	0.0046	$C_{18}H_{30}Cl_2O_6$	411.1300
Difference to compound 4	ds	Tri- chlorinated compound	
Putative positional isomer	0.0032	C15H25Cl3O4	373.0713
$+ C_3H_4O_2$ (putative bis-lactylate)	0.0050	$C_{18}H_{29}Cl_{3}O_{6}$	445.0906




Figure 4. Mass spectra of the putative mono- (A), di- (B), and tri- (C) chlorinated bislactylates. Since the position of the chlorine atoms could not be ascertained, in order to rationalize the analysis of the ions generated by the in-source fragmentation, the chlorinated moiety is represented by its molecular formula. Mass differences are shown in grey and black color. The loss of chlorine atoms is also confirmed by change in the isotope pattern.

The chlorosphaerolactylates **A-D** were isolated on the basis of an antibacterial screening. Thus, compounds **1** and **4** as well as mixture of compounds **2/3** (51:33 ratio) were tested for antibacterial and antifungal activities using resistant strains driven from clinical isolates: *Escherichia coli* AR, *Staphylococcus aureus* S54F9²³, and *Candida parapsilosis* SMI416²⁴ (Table 3). The chlorosphaerolactylates inhibited the growth of *S. aureus* and C. *parapsilosis* in

- the range of concentrations between 1024-2048 µg/mL. No antibacterial effect was observed
- 218 against the clinical isolate *E. coli*.
- 219

220	Table 3. Antibacterial, antifungal and antibiofilm activities of compounds 1-4.

	Antiba	acterial /Antifu	Antibiofilm activity		
	I	MBC ^a /MFC ^b (µ	MBIC50 ^c (µg/mL)		
	E. coli	oli S. aureus C. parapsilosis		Coagulase-negative	
Compound	AR	S54F9	SMI416	Staphylococcus FI31	
1	NI	2048	1024	200	
2/3 (51:33)	NI	1024	1024	313	
4	NI	1024	2048	430	

^aMBC: minimum bactericidal concentration; ^bMFC: minimum fungicidal concentration; ^cMBIC₅₀: minimum concentration of the test compound that resulted in \geq 50% inhibition of biofilm formation. NI: no inhibition at the highest tested concentration (2048 µg/mL)

221

Moreover, antibiofilm activity was assessed against coagulase-negative *Staphylococcus* FI31 (Table 3), a clinical isolate collected from an infected prosthesis. The compounds **1**, **2**/**3** and **4** were able to reduce the biofilm formation showing a 3 fold-decrease in optical density (OD) in comparison with the OD obtained for the positive control, with MBIC₅₀ values of 200, 313 and 430 μ g/mL, respectively.

227

228 Concerning the antibacterial effects of lactylates, most of what is found in the literature derives 229 from patents. For instance, the patent document WO2018222184A1²⁵ refers to antimicrobial 230 compositions, which include an acyl lactylate, for inhibiting microbial growth in personal care 231 products. Likewise, compositions with fatty acid esters as the predominant component were subject of the US6878757B2²⁶ patent as an antimicrobial coating for absorbable surgical
articles. Furthermore, the patent document US7973006B2²⁷ describes the use of an
antibacterial agent (composed of mono- and/or di-lactylate esters of octanoic acid, or decanoic
acid, or dodecanoic acid, or tetradecanoic acid, or palmitic acid, or oleic acid) against gramnegative bacteria (*Escherichia coli, Salmonella, Pseudomonas* or *Campylobacter*).

237

In conclusion, this study describes the structure of four novel chlorosphaerolactylates, isolated from the cyanobacteria *Sphaerospermopsis* sp. LEGE 00249, with antibiofilm and antibacterial and antifungal properties. In addition, other putative chlorosphaero(bis)lactylates were also reported for the first time. These findings taken together, add to the knowledge of the fascinating world of cyanobacterial secondary metabolites, namely to the class of halogenated fatty acid derivatives.

244

245

246 **Experimental section**

247

culture conditions. 248 Cyanobacterial strain and The cyanobacterium strain Sphaerospermopsis sp. LEGE 00249 was obtained from the LEGE CC³¹. The detection of 249 250 compounds was performed using biomass of cultures grown in laboratory conditions. The strain was cultured up to 50 L in Z8 medium³² at 25 °C, with constant aeration with a 251 252 photoperiod of 14 h/10 h light and dark respectively, and at light intensity of 10-30 µmols photons s⁻¹.m⁻². At the exponential phase, cells were harvested through centrifugation, then 253 254 frozen and freeze-dried. In order to obtain larger amount of biomass from Sphaerospermopsis 255 sp. LEGE 00249, that could allow the isolation and chemical characterization of compounds 1-4, the culture was scaled-up in outdoor conditions. In this context, the strain was cultivated 256

in a modified BG11 medium³³ and gradually adapted to outdoor conditions in particular with 257 regards to light intensity and photoperiod using as culture vessel a 7-L bubbled tube placed 258 259 outdoors. A volume containing 15 g of dry biomass was then transferred to a 40-L Green Wall 260 Panel (GWP®-III) photobioreactor in order to start with an initial biomass concentration of 20 g.m⁻² of reactor illuminated surface. For the first days, the photobioreactor was tilted backward 261 262 (North facing) to reduce the light intercepted and thus reduce light stress to the culture, then it was tilted (50°) facing South to increase light availability and thus maximize growth and 263 productivity. The culture was kept at a maximum temperature of 28 °C by circulating cold 264 265 water inside a stainless-steel serpentine placed within the culture chamber and it was bubbled with air at a flow rate of 0.3 $L.L^{-1}$ min⁻¹. Pure CO₂ was injected when the pH value exceeded 266 267 7.8. The culture was firstly managed in batch and then in semi-continuous with a 30% daily dilution. Average productivity was 7.6 g.m⁻².day⁻¹ with an average irradiance of 29.6 MJ.m⁻ 268 ².day⁻¹. The culture was harvested at the steady-state by centrifugation, then frozen and 269 lyophilized. 270

271

272 Bacterial strains and culture conditions. Escherichia coli clinical isolate (AR-collected from urine at the Hospital Clinic of Barcelona), Staphylococcus aureus spa type t1333 (S54F9)²³ 273 and Candida parapsilosis clinical isolate from bloodstream infection (SMI416)²⁴ were 274 275 employed for antibacterial and antifungal activities. E. coli, S. aureus and C. parapsilosis were 276 resuscitated on MH agar (Mueller-Hinton Agar, Oxoid) at 37 °C from 25 % glycerol (v/v) stocks kept at -20 °C, and maintained thereafter at 4 °C. Coagulase-negative Staphylococcus 277 278 FI31 is a clinical isolated collected from an infected prosthesis at the Hospital Clinic of 279 Barcelona. Bacterial culture media were purchased from ThermoScientific. All other solutions 280 and media were made with ultrapure deionized water and were sterilized by autoclaving at 121 281 °C for 15 min.

282 Antibiotic assays. The antimicrobial properties of the three crude extracts (hexane, ethyl 283 acetate and methanol), the fractions obtained in the different purification steps, as well as of 284 the isolated compounds 1-4, were tested via microdilution assay following the guidelines of the two established organizations and committees, the CLSI³⁴ and EUCAST³⁵. MBC/MFC 285 (Minimum Bactericidal/Fungicidal Concentration) was determined according to CLSI protocol 286 287 by plating 20 uL from each well showing no visible growth at 24 h onto a solid medium. The lowest concentration of the compound that killed > 99.9 % of the initial inoculum was 288 289 determined to be the MBC/MFC. The antibiotic activity of the extracts and molecules was 290 determined using 96-well U-bottom microtiter plates (ThermoScientific). Microorganisms 291 were grown overnight (37 °C, 250 rpm) and diluted in MHB (Mueller-Hinton Broth, Oxoid) 292 up to the desired cell density. When crude extracts and HPLC fractions were tested for 293 bioactivity-guided fractionation purposes, no serial dilutions were performed (yes/no method) 294 and only for compounds 1-4 two-fold dilutions were carried out in order to obtain a MBC/MFC 295 value. Both protocols are described below. In order to perform antibiotic susceptibility tests of 296 crude extracts and HPLC fractions, 50 µL of each HPLC fraction or crude extract resuspended 297 in 14% MeOH in water (v/v) were mixed with 50 µL of the Staphylococcus aureus S54F9 suspension at 10⁶ CFU/mL in 2x MHB in a microtiter plate and incubated statically overnight 298 at 37 °C (final desired inoculum = 5.10^5 CFU/mL, final concentration of MeOH in bioassay 299 300 plate = 7% (v/v), final volume per well = 100 μ L). Growth controls (broth with bacterial 301 inoculum, no bioactive molecule) as well as sterility (broth only) and solvent controls (bacterial 302 inoculum with a final concentration of 7% MeOH in water v/v) were included.{Formatting 303 Citation } Microbial sedimentation was checked by visual verification and each experiment was 304 performed in duplicate. The microtiter plate was replicated onto a selective/differential solid 305 medium such as Mannitol Salt Agar (SMA, VWR Chemicals) with a 96-pin replicator in order 306 to distinguish between bacteriostatic and bactericidal activities.

307 When compounds 1-4 were tested for antibiotic activity, stock solutions in MeOH 28% (v/v) 308 were prepared at a concentration of 8192 µg/mL which resulted in a final concentration in the 309 first dilution well of 1024 µg/mL. 50 µL of water were added to each well except to the solvent 310 control (bacterial inoculum with a final concentration of 7% MeOH in water v/v) and 50 µL of 311 each compound (per duplicate) were added to the first well of each row and two-fold serial 312 dilutions were performed transferring 50 µL to the following well. Finally, 50 µL of each 313 microorganism at 10⁶ CFU/mL (S. aureus and E. coli) in 2 x MHB were added (final 314 concentration of MeOH in bioassay plate = 7%, final volume per well = 100μ L); in the case of *C. parapsilosis*, the cells concentration was $5 \cdot 10^5$ CFU/mL. Growth and sterility controls 315 316 were included as well. The microtiter plate was replicated onto a selective/differential solid 317 medium depending on each microorganism: Eosin Methylene Blue Agar for E. coli (EMB, 318 Merck Chemicals), Mannitol Salt Agar for S. aureus (SMA, VWR Chemicals) and Sabouraud 319 Dextrose Agar for C. parapsilosis (VWR Chemicals).

320

321 Antibiofilm assays. The pure compounds were resuspended with 150 µL of DMSO 10% (final 322 concentration 5%). Fifty µL of each extract was added into well and serial diluted with 50 µL of bacterial suspension at a concentration of 10⁶ CFU/mL in TSB culture medium. The plates 323 324 were incubated for 48 h at 37 °C. The plates were washed with sterile 1X phosphate-buffered 325 saline (PBS) and stained with 200 µL of 0.2% crystal violet (CV). CV was resuspended using 326 a 3% glacial acetic acid solution and optical density read in a spectrophotometer at 580 nm. 327 All the experiments were carried out in duplicate. A negative control (culture medium without 328 inoculum) and a positive control (culture medium with inoculum) were included in each plate. 329 All the plates were covered with adhesive foil lids to avoid evaporation. The MBIC was defined 330 as the lowest concentration of drug that resulted in a three-fold decrease of the optical density 331 of 580 nm (OD580) in comparison with the positive growth-control value. The biofilm

inhibition rates were calculated using the equation: $100 \times (1 - OD_{580} \text{ of the test/OD}_{580} \text{ of non-}$ treated control). The MBIC₅₀ was defined as the lowest concentration that caused 50% inhibition on the formation of biofilm.

335

336 General chemical experimental procedures. Optical rotation was obtained using a P-2000 337 polarimeter (JASCO). Infrared spectrum was collected on a Nicolet iS5 FTIR spectrometer 338 (ThermoScientific). The 1D and 2D NMR spectrometric data were measured on a Bruker AV600 spectrometer equipped with a 5 mm ¹H, ¹³C, ¹⁵N, ³¹P cryoprobe working at a ¹H 339 frequency of 600.13 MHz and ¹³C frequency of 150.9 MHz. NMR samples were prepared by 340 341 dissolving the fraction in 0.5 mL of CD₃OD and transferring the solution to a 5 mm NMR tube. 342 The structural elucidation was based on the analysis of a set of 1D and 2D NMR spectra including ¹H, gNOESY-¹H (water suppression), ¹³C, COSY, HSQC edited and HMBC. The 343 344 solvent signal was used as internal NMR reference. Standard Bruker software (TopSpin 3.6) was used for the acquisition and processing of the 1D and 2D NMR spectra. 345

Bioactivity-guided fractionation and LC-MS analysis of the antibacterial fractions. The
 procedure is supplied in the Supporting Information.

348 Consecutive isolations of compound 1, 2, 3 and 4. The isolation procedure is supplied in the
349 Supporting Information.

350 *Chlorosphaerolactylate A ([(6,12-dichlorododecanoyl)oxy]propanoic acid)* (1): light-green 351 oil; $[\alpha]^{24}_{D}$ +33.1 (c 0.01, MeOH); IR (KBr) v_{max} 2937, 1736 and 1725 cm⁻¹; ¹H and ¹³C NMR 352 spectroscopic data (CD₃OD), see Table 1; HRMS m/z 339.1117 [M-H]⁻ (calcd for C₁₅H₂₆Cl₂O₄ 353 = 339.1135).

- 354 *Chlorosphaerolactylate B ([(12-chlorododecanoyl)oxy]propanoic acid)* (2): light-yellow oil;
- 355 ¹H and ¹³C NMR spectroscopic data (CD₃OD), see Table 1; HRMS m/z 305.1504 [M-H]⁻ 356 (calcd for $C_{15}H_{27}ClO_4 = 305.1525$).
- 357 *Chlorosphaerolactylate C ([(6-chlorododecanoyl)oxy]propanoic acid)* (3): light-yellow oil;;
- ¹H and ¹³C NMR spectroscopic data (CD₃OD), see Table 1; HRMS m/z 305.1509 [M-H]⁻
- 359 (calcd for $C_{15}H_{27}ClO_4 = 305.1525$).
- 360 Chlorosphaerolactylate D ([(6,12,12-trichlorododecanoyl)oxy]propanoic acid) (4): light-
- 361 green oil; ¹H and ¹³C NMR spectroscopic data (CD₃OD), see Table 1; HRMS m/z 373.0707
- 362 $[M-H]^-$ (calcd for C₁₅H₂₅Cl₃O₄ = 373.0746)
- 363
- 364 AUTHOR INFORMATION
- 365 Corresponding Author
- ³⁶⁶ * Mariana A. Reis, <u>mreis@ciimar.up.pt</u>, Interdisciplinary Centre of Marine and Environmental
- 367 Research (CIIMAR/CIMAR), Terminal de Cruzeiros do Porto de Leixões, University of Porto,
- 368 4450-208 Matosinhos, Portugal
- 369 * Fernando Lopez Ortiz, flortiz@ual.es, Área de Química Orgánica, Research Centre
- 370 CIAIMBITAL, Universidad de Almería, Ctra. Sacramento s/n, 04120, Almería, Spain.
- 371

372 Author Contributions

- ³⁷³ ^O I.G.R., N.B.F. and R.C.B contributed equally to this work sharing the first co-authorship.
- 374 I.G.R. and S.R.B. performed the antibiotic assays I.G.R. conducted the bioassay-guided
- 375 fractionation and the HRESIMS experiments for identification of putative
- 376 chlorosphaero(bis)lactylates. F.L. and C.J.V supervised the work described for I.G.R. and

377 S.R.B. I.G.R. and F.L. contributed to the writing of the paper. N.B.F., R.C.B and M.A.R 378 isolated compounds 1-4 from large scale biomass, determined the optical rotation of 1 and 379 significantly contributed to the writing of the paper. F.O. and J. M. performed lab scale growth 380 and extractions and V.V. supervised the works described for N.B.F., R.C.B, M.A.R, F.O. and 381 J. M. M.J.I., R.S. and F.L.O. acquired the NMR data, and performed and wrote the structure 382 elucidation of compounds 1-4. V.C. and Y.L.C. performed the antibiofilm assays under the supervision of S.S.G. G. S. and L. R. performed the large scale growth in outdoor conditions. 383 384 M.A.R. took the lead in writing and revising the manuscript using the inputs from all the 385 authors. All authors have given approval to the final version of the manuscript.

386

387 Acknowledgments

388 This work was funded by the European Commission under the H2020 program, NoMorFilm 389 Project (Grant Agreement 634588). CIIMAR was additionally supported by the FCT strategic 390 fund UID/Multi/04423/2019. R.C.B. acknowledges financial support from a Fundação para a 391 Ciência e a Tecnologia (FCT) fellowship SFRH/BD/136367/2018. University of Oviedo also 392 thanks Programa de Ayudas a Grupos de Investigación del Principado de Asturias 393 (IDI/2018/000120) and Programa Severo Ochoa de Ayudas Predoctorales para la 394 investigación y docencia from Principado de Asturias (grant BP16023 to I.G.R.). HRESIMS 395 experiments were conducted at the Mass spectrometry unit of the University of Oviedo 396 (Servicios Científico-Técnicos). ISGlobal is a CERCA center from the Generalitat of 397 Catalunya and a Severo Ochoa Center (Spanish Ministry of Science, Innovations and 398 Universities) supported by Planes Nacionales de I+D+i 2008-2011 / 2013-2016 and Instituto 399 de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, 400 Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious

401	Diseases (REIPI RD12/0015/0013 and REIPI RD16/0016/0010) co-financed by European
402	Development Regional Fund "A way to achieve Europe" and operative program Intelligent
403	Growth 2014-2020.
404	

-

405	References

406

407	(1)	Dittmann, E.; Gugger, M.; Sivonen, K.; Fewer, D. P. Natural Product Biosynthetic
408		Diversity and Comparative Genomics of the Cyanobacteria. Trends Microbiol. 2015,

409 23 (10), 642–652. https://doi.org/10.1016/j.tim.2015.07.008.

- 410 (2) Newman, D. J.; Cragg, G. M. Natural Products as Sources of New Drugs from 1981 to
- 411 2014. J. Nat. Prod. 2016, 79 (3), 629–661.
- 412 https://doi.org/10.1021/acs.jnatprod.5b01055.
- 413 (3) Demay, J.; Bernard, C.; Reinhardt, A.; Marie, B. Natural Products from
- 414 Cyanobacteria: Focus on Beneficial Activities. *Mar. Drugs* **2019**, *17* (6), 1–49.
- 415 https://doi.org/10.3390/md17060320.
- 416 (4) Dembitsky, V. M.; Srebnik, M. Natural Halogenated Fatty Acids: Their Analogues and
- 417 Derivatives. Prog. Lipid Res. 2002, 41 (4), 315–367. https://doi.org/10.1016/S0163-
- 418 7827(02)00003-6.
- 419 (5) Gribble, G. W. Natural Organohalogens: A New Frontier for Medicinal Agents? J.
- 420 *Chem. Educ.* **2004**, *81* (10), 1441–1449. https://doi.org/10.1021/ed081p1441.
- 421 (6) Atashgahi, S.; Häggblom, M. M.; Smidt, H. Organohalide Respiration in Pristine
- 422 Environments: Implications for the Natural Halogen Cycle. *Environ. Microbiol.* **2018**,
- 423 20 (3), 934–948. https://doi.org/10.1111/1462-2920.14016.
- 424 (7) Neumann, C. S.; Fujimori, D. G.; Walsh, C. T. Halogenation Strategies In Natural
- 425 Product Biosynthesis. *Chem. Biol.* **2008**, *15* (2), 99–109.

- 426 https://doi.org/10.1016/j.chembiol.2008.01.006.
- 427 (8) Kan, Y.; Sakamoto, B.; Fujita, T.; Nagai, H. New Malyngamides from the Hawaiian
 428 Cyanobacterium Lyngbya Majuscula. *J. Nat. Prod.* 2000, *63* (12), 1599–1602.
- 429 https://doi.org/10.1021/np000250t.
- 430 (9) Edwards, D. J.; Marquez, B. L.; Nogle, L. M.; Mcphail, K.; Goeger, D. E.; Roberts, M.
- 431 A.; Gerwick, W. H. CNTNAP2 Is Significantly Associated with Schizophrenia and
- 432 Major Depression in the Han Chinese Population. *Psychiatry Res.* 2012, *1* (1), 817–
 433 833. https://doi.org/10.1016/j.
- 434 (10) Jiménez, J. I.; Vansach, T.; Yoshida, W. Y.; Sakamoto, B.; Pörzgen, P.; Horgen, F. D.
- 435 Halogenated Fatty Acid Amides and Cyclic Depsipeptides from an Eastern Caribbean
- 436 Collection of the Cyanobacterium Lyngbya Majuscula. J. Nat. Prod. 2009, 72 (9),
- 437 1573–1578. https://doi.org/10.1021/np900173d.
- 438 (11) Lopez, J. A. V.; Petitbois, J. G.; Vairappan, C. S.; Umezawa, T.; Matsuda, F.; Okino,
- 439 T. Columbamides D and E: Chlorinated Fatty Acid Amides from the Marine
- 440 Cyanobacterium Moorea Bouillonii Collected in Malaysia. Org. Lett. 2017, 19 (16),
- 441 4231–4234. https://doi.org/10.1021/acs.orglett.7b01869.
- 442 (12) Moore, R. E.; Bornemann, V.; Niemczura, W. P.; Gregson, J. M.; Chen, J. L.; Norton,
- 443 T. R.; Patterson, G. M. L.; Helms, G. L. Puwainaphycin C, a Cardioactive Cyclic
- 444 Peptide from the Blue-Green Alga Anabaena BQ-16-1. Use of Two-Dimensional
- 445 Carbon-13-Carbon-13 and Carbon-13-Nitrogen-15 Correlation Spectroscopy in
- 446 Sequencing the Amino Acid Units. J. Am. Chem. Soc. **1989**, 111 (16), 6128–6132.
- 447 https://doi.org/10.1021/ja00198a021.
- 448 (13) Luesch, H.; Yoshida, W. Y.; Moore, R. E.; Paul, V. J.; Mooberry, S. L. Isolation,
- 449 Structure Determination, and Biological Activity of Lyngbyabellin A from the Marine
- 450 Cyanobacterium Lyngbya majuscula. J. Nat. Prod. 2000, 63 (5), 611–615.

451 https://doi.org/10.1021/np990543q.

- 452 (14) Mercer, E. I.; Davies, C. L. Chlorosulpholipids in Algae. *Phytochemistry* 1975, *14* (7),
 453 1545–1548. https://doi.org/10.1016/0031-9422(75)85348-9.
- 454 (15) Moosmann, P.; Ueoka, R.; Gugger, M.; Piel, J. Aranazoles: Extensively Chlorinated
- 455 Nonribosomal Peptide-Polyketide Hybrids from the Cyanobacterium Fischerella Sp.
- 456 PCC 9339. Org. Lett. 2018, 20 (17), 5238–5241.
- 457 https://doi.org/10.1021/acs.orglett.8b02193.
- 458 (16) Cepas, V.; López, Y.; Gabasa, Y.; Martins, C. B.; Ferreira, J. D.; Correia, M. J.;
- 459 Santos, L. M. A.; Oliveira, F.; Ramos, V.; Reis, M.; et al. Inhibition of Bacterial and
- 460 Fungal Biofilm Formation by 675 Extracts from Microalgae and Cyanobacteria.

461 *Antibiotics* **2019**, 8 (2), 1–12. https://doi.org/10.3390/antibiotics8020077.

- 462 (17) Martins, J.; Leikoski, N.; Wahlsten, M.; Azevedo, J.; Antunes, J.; Jokela, J.; Sivonen,
- 463 K.; Vasconcelos, V.; Fewer, D. P.; Leão, P. N. Sphaerocyclamide, a Prenylated
- 464 Cyanobactin from the Cyanobacterium Sphaerospermopsis Sp. LEGE 00249. *Sci. Rep.*

465 **2018**, 8 (1), 1–9. https://doi.org/10.1038/s41598-018-32618-5.

- 466 (18) Aalbæk, B.; Jensen, L. K.; Jensen, H. E.; Olsen, J. E.; Christensen, H. Whole-Genome
- 467 Sequence of Staphylococcus Aureus S54F9 Isolated from a Chronic Disseminated
- 468 Porcine Lung Abscess and Used in Human Infection Models. *Genome Announc.* 2015,
- 469 *3* (5), 9–10. https://doi.org/10.1128/genomeA.01207-15.
- 470 (19) Boutte, T.; Skogerson, L. Stearoyl-2-Lactylates and Oleoyl Lactylates. *Emuls. food*471 *Technol.* 2004, 206–225.
- 472 (20) Wang, F. C.; Marangoni, A. G. Advances in the Application of Food Emulsifier α-Gel
- 473 Phases: Saturated Monoglycerides, Polyglycerol Fatty Acid Esters, and Their
- 474 Derivatives. J. Colloid Interface Sci. 2016, 483, 394–403.
- 475 https://doi.org/10.1016/j.jcis.2016.08.012.

- 476 (21) Shah, R.; Kolanos, R.; DiNovi, M. J.; Mattia, A.; Kaneko, K. J. Dietary Exposures for
- 477 the Safety Assessment of Seven Emulsifiers Commonly Added to Foods in the United
- 478 States and Implications for Safety. *Food Addit. Contam. Part A* **2017**, *34* (6), 905–917.
- 479 https://doi.org/10.1080/19440049.2017.1311420.
- 480 (22) Draelos, Z. D.; Donald, A. The Effect of an Anti-Inflammatory Botanical
- 481 Cleanser/Night Mask Combination on Facial Redness Reduction. *J. Drugs Dermatol.*482 **2018**, *17* (6), 671–676.
- 483 (23) Aalbæk, B.; Jensen, L. K.; Jensen, H. E.; Olsen, J. E.; Christensen, H. Whole-Genome
- 484 Sequence of Staphylococcus Aureus S54F9 Isolated from a Chronic Disseminated
- 485 Porcine Lung Abscess and Used in Human Infection Models. *Genome Announc.* 2015,
- 486 *3* (5). https://doi.org/10.1128/genomeA.01207-15.
- 487 (24) Pannanusorn, S.; Ramírez-Zavala, B.; Lünsdorf, H.; Agerberth, B.; Morschhäuser, J.;
- 488 Römling, U. Characterization of Biofilm Formation and the Role of BCR1 in Clinical
- 489 Isolates of Candida Parapsilosis. *Eukaryot. Cell* **2014**, *13* (4), 438–451.
- 490 https://doi.org/10.1128/EC.00181-13.
- 491 (25) Jeffery, R.; Paige, N.; Corey, T.; Luke, D. WO2018222184A1: Antimicrobial
- 492 Composition Including an Acyl Lactylate and a Glycol and Methods of Inhibiting
- 493 Microbial Growth Utilizing the Same, 2018.
- 494 (26) Roby, M. US6878757B2: Antimicrobial Suture Coating, 2005.
- 495 (27) Ramirez, M.; Kremer, D. R. US7973006B2: Antibacterial Agent based on Fatty Acid
 496 Esters of Hydroxy Carboxilic Acid, 2011.
- 497 (28) Stenbæk, J.; Löf, D.; Falkman, P.; Jensen, B.; Cárdenas, M. An Alternative Anionic
- 498 Bio-Sustainable Anti-Fungal Agent: Investigation of Its Mode of Action on the Fungal
- 499 Cell Membrane. J. Colloid Interface Sci. 2017, 497, 242–248.
- 500 https://doi.org/10.1016/j.jcis.2017.03.018.

- 501 (29) Code of Federal Regulations. Food and Drugs Sodium Stearoyl Lactylate
 502 (21CFR172.846).
- 503 (30) EFSA Panel on Dietetic Products, N.; (NDA), A. Scientific Opinion on the
- 504 Substantiation of Health Claims Related to Lactulose and Decreasing Potentially
- 505 Pathogenic Gastro-Intestinal Microorganisms (ID 806) and Reduction in Intestinal
- 506 Transit Time (ID 807) Pursuant to Article 13(1) of Regulation (EC) N. EFSA J. 2010,
- 507 8 (10), 1806. https://doi.org/10.2903/j.efsa.2010.1806.
- 508 (31) Ramos, V.; Morais, J.; Castelo-Branco, R.; Pinheiro, Â.; Martins, J.; Regueiras, A.;
- 509 Pereira, A. L.; Lopes, V. R.; Frazão, B.; Gomes, D.; et al. Cyanobacterial Diversity
- 510 Held in Microbial Biological Resource Centers as a Biotechnological Asset: The Case
- 511 Study of the Newly Established LEGE Culture Collection. J. Appl. Phycol. 2018, 30

512 (3), 1437–1451. https://doi.org/10.1007/s10811-017-1369-y.

- 513 (32) Kotai, J. Instructions for Preparation of Modified Nutrient Solution Z8 for Algae. *Inst.*514 *Water Res. Blind.* 1972.
- 515 (33) Rippka, R. [1] Isolation and Purification of Cyanobacteria; 1988; pp 3–27.
- 516 https://doi.org/10.1016/0076-6879(88)67004-2.
- 517 (34) Wiegand, I.; Hilpert, K.; Hancock, R. E. W. Agar and Broth Dilution Methods to
- 518 Determine the Minimal Inhibitory Concentration (MIC) of Antimicrobial Substances.
- 519 *Nat. Protoc.* **2008**, *3* (2), 163–175. https://doi.org/10.1038/nprot.2007.521.
- 520 (35) Determination of Minimum Inhibitory Concentrations (MICs) of Antibacterial Agents
- 521 by Broth Dilution. *Clin. Microbiol. Infect.* **2003**, *9* (8), ix–xv.
- 522 https://doi.org/10.1046/j.1469-0691.2003.00790.x.